about ttx
Who We Are
Triterpenoid Therapeutics (TTX) is developing brain-penetrant therapeutics that target the root causes of neurodegenerative diseases and brain cancers, conditions that have resisted treatment for decades.
Our approach is unique: we simultaneously address both inflammation (through NLRP3) and cellular stress (through the ISR), two overlapping drivers of brain disease. Our lead compound, TTX-01, is designed to be the most potent triterpenoid ever developed, with proven ability to cross the blood-brain barrier and demonstrated efficacy in preclinical models.
OUR STORY
Built on Decades of Discovery
TTX continues the pioneering work of our founder, Dr. Michael B. Sporn, who transformed cancer prevention over five decades at the National Cancer Institute. Our compounds evolved from nature's own healing molecules - triterpenoids found in medicinal plants - enhanced through systematic optimization.
Validated by FDA Approval
Our scientific foundation is proven: Omaveloxolone (Skyclarys™) shares our core molecular scaffold and received FDA approval in 2023. This validation supports both the safety and therapeutic potential of our approach.
Designed to Transform Treatment
Unlike single-target drugs that often fail in complex brain diseases, TTX compounds work through dual mechanisms to restore cellular health while complementing existing therapies. This comprehensive approach opens immediate opportunities to improve outcomes for patients with limited options.